Seasoned industry executive with decades of success in drug discovery, development, regulatory approvals and commercialization will lead Nereid's work to advance multiple programs towards the clinic
BOSTON, Nov. 13, 2023 /PRNewswire/ -- Nereid Therapeutics, a biotechnology company that is discovering new disease treatments by applying pioneering research and technologies to biomolecular condensates, announced today that
Michael Kauffman, M.D., Ph.D., has joined the company as President and Chief Executive Officer. Dr. Kauffman will also join the Nereid Board of Directors.
Spiros Liras, Ph.D., a venture partner at Apple Tree Partners (ATP) who has been acting CEO of Nereid since the company was created by ATP in late 2020, will continue to serve on Nereid's Board of Directors and the company's Scientific Advisory Board.
"We are delighted to welcome Michael to Nereid at a pivotal juncture when, having demonstrated translatability of chemical matter that modulates liquid-liquid phase separation behavior to disease-relevant cellular phenotypes, we are now rapidly progressing several programs addressing high-value targets in cancer and other diseases," Dr. Liras said. "Michael brings to Nereid the right energy at the right time. He combines proven experience in leading teams delivering lifesaving therapies from the laboratory to patients, deep expertise in all aspects of industry, and a drive and passion to apply Nereid's groundbreaking science to achieve significant medical breakthroughs."
"This is a transformational time to join Nereid as we enter a new phase of development and advance multiple programs in oncology and neurodegeneration towards the clinic," Dr. Kauffman said. "I look forward to working alongside this highly talented team who are pioneers in the novel, exciting and highly physiologically relevant field of biomolecular condensate science, which is the core of Nereid's approach to drug discovery and development."
Dr. Kauffman and other members of the Nereid leadership team will be onsite for meetings at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024, in San Francisco, CA.
Nereid Therapeutics, an ATP company, is discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and the resulting biomolecular condensates. Based on groundbreaking discoveries and technologies pioneered by 2023 Breakthrough Prize winner Cliff Brangwynne, Ph.D., Nereid applies leading expertise in soft matter physics and cell biology to pioneer completely new ways to fight intractable diseases. For more information, visit nereidtx.com.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.